the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Category | Publishers | Custom Research | E-mail Alert | About Us | Contact Us | Site Map |
 

* View All Categories
View Conferences
Japanese Korean Chinese

Market Research Report

Immune/Inflammatory Disease: Early-Stage R&D Technologies and Dealmaking

Published by Decision Resources, Inc. Contact us : +1-860-674-8796
Published 2009/05 Content info 24 Pages
Product code DR87288
Price From  US $ 2250 Order/Price list
US $ 2250 PDF by E-mail (Single User License)
Delivery Time
PDF by E-Mail
Approx. 1-2 business days
Hard Copy/CD-ROM
Approx. 3-4 business days
If you need expedited delivery, please call us.
Description TOC

Abstract

Introduction

Today' s leading autoimmune/infl ammatory disease drugs are blockbusters, but what are the remaining unmet needs and next opportunities? Dealmaking patterns indicate that Big Pharma continues to look to small technology companies to tap opportunities to treat underserved diseases and offer improved administration options. While the value of the novel agents in development remains unproved, earlystage platforms and pipelines house the next innovations in these disease states.

Get the Answers You Need to Shape Your Strategy

  • Although effi cacious, current therapies for infl ammatory and autoimmune diseases do not successfully treat all patients. What novel mechanisms of action are in development? What technologies offer treatment potential?
  • Much of the innovation in drug discovery and design occurs in small companies. What companies are developing novel approaches to treat infl ammatory diseases? What collaborations have they forged with Big Pharma?
  • Although the infl ammatory cascade is central to most of the autoimmune diseases, the specifi c etiology of many diseases remains unknown. What are companies doing to further the understanding of these diseases?

Scope

  • Current market: 2008 sales, market-leading products, leading companies.
  • Novel targets for drug development: MAP kinases, Janus kinases, toll-like receptors, novel interleukins, NF-κB, PDE4.
  • Novel technologies for drug development: RNA therapeutics, stem-cell therapy.
  • Development and dealmaking data: 8 tables that identify developmental compounds and industry and academic alliances.
  • Company profi les: Archemix, Array BioPharma, Cellzome, Dynavax, Regulus Therapeutics.

Companies Mentioned in This Spectrum Report

  • Abbott
  • Adeona Pharmaceuticals
  • Amgen
  • Anacor Pharmaceuticals
  • Anesiva
  • AnGes MG
  • Archemix
  • Ardea
  • Array BioPharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Cellzome
  • Centocor
  • Cytokine Pharmasciences
  • Cytos Biotechnology
  • Dainippon Sumitomo
  • Dynavax
  • Eisai
  • Eli Lilly
  • Genzyme
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Hutchison Medipharma
  • Idera Pharmaceuticals
  • Incyte
  • Institute of Medicinal Molecular Design
  • Kemia
  • Ligand
  • Merck
  • Merck Serono
  • Mitsubishi Tanabe
  • MorphoSys
  • Novartis
  • Nycomed
  • Osiris
  • Otsuka Pharmaceutical
  • Pfi zer
  • Reata Pharmaceuticals
  • Regulus Therapeutics
  • Rigel Pharmaceuticals
  • Roche
  • RXi Pharmaceuticals
  • Sanofi -Aventis
  • Schering-Plough
  • Sigma-Aldrich
  • Silence Therapeutics
  • Synta Pharmaceuticals
  • Takeda
  • Transcription Factor Therapeutics
  • Verona Pharma
  • Vertex Pharmaceuticals
  • VGX Pharmaceuticals
  • Wyeth
  • Znomics
Related Report
Back to Top
Please inform me when related publications are released
InfoWatch

US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2009, the-infoshop.com by Global Information, Inc. All rights reserved.